期刊文献+

妇科恶性肿瘤化疗后骨髓抑制处理中的实用问题 被引量:34

下载PDF
导出
摘要 骨髓抑制是妇科恶性肿瘤化学治疗(化疗)后常见而重要的副反应。对化疗后骨髓抑制的一般规律及其意义、骨髓抑制作用突出的常用化疗药物、骨髓抑制的病理生理及总体处理原则进行了总结,并分别对化疗后贫血、粒细胞减少和血小板减少的处理中常见问题进行了阐述,还对目前骨髓抑制治疗中三类重要的生长因子类药物即重组人红细胞生成素,重组粒细胞集落刺激因子和促血小板生成素的使用指征、使用方法和技巧等进行了探讨。
机构地区 北京协和医院
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2009年第5期272-274,共3页 Journal of Practical Obstetrics and Gynecology
  • 相关文献

参考文献7

  • 1Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red cell transfusions: developed by the Red Blood Coil Administration Practice Guidelines Development Task Force of the College of American Pathologists [J]. Arch Pathol Lab Med, 1998,122(2):130- 138.
  • 2Rizzo JD, Linchtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and American Society of Hematology [J]. J Clin Oncol,2002,20(19) :4083 - 4107.
  • 3Ozer H, Armitage JO, Bennett CL, et al. Update of recommendations of hematopoietic colony stimulating factors: evidence-based clinical practice guidelines [J]. J Clin Oncol,2000,18(20) :3558 - 3585.
  • 4Huvel K, Engert A. Clinical applications of granulocyte colony-stimulating factor:an update and summary [J]. Ann Hematol,2003,82(4):207- 213.
  • 5Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patient with cancer: clinical practice guidelines of the American Society of Clinical Oncology [J]. J Clin Oncol,2001,19(5) : 1519 - 1538.
  • 6白春梅,邹晓阳,赵永强,韩少梅,单渊东,血小板生成素临床试验协作组.重组人血小板生成素治疗化疗诱导的重度血小板减少的临床研究[J].中华医学杂志,2004,84(5):397-400. 被引量:32
  • 7黄梅,张东华,刘文励,孙汉英,邓金牛,周剑锋.重组人血小板生成素的临床应用观察[J].内科急危重症杂志,2005,11(1):34-36. 被引量:6

二级参考文献8

  • 1Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c_Mpl ligand thrombopoietin. Nature, 1994, 369: 568.
  • 2Borge OJ, Rarnsfjell V, Veiby OP, et al. Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro.Blood, 1996, 88: 2859.
  • 3David J, Kuter and C, Glenn Begley. Recombinant human thrombopoietin: basic biology and evalution of clinical studies Blood,2002,100: 3457.
  • 4Archimbaud E, Ottmann OG, Yin JA, et al. A randomized,double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood, 1999,94: 3694.
  • 5Nash R, Kurzrock R, Dipersio J, et al. Safety and activity of recombinant human thrombopoietin(rhTPO) in patients(pts) with delayed platelet reco-very(DPR). Blood, 1997,90: 262a.
  • 6Dan K, Nomura S, Hotta T, et al. Biological effect of pegylated recombinant human megakaryocyte growth and development factor(PEG-rHuMGDF) in patients with idiopathic thrombocytopenic purpura. Blood,2001,98: 299.
  • 7赵永强,姜杰玲,焦力,潘家琦,陈书长,王书杰,单渊东,沈悌,武永吉.重组人血小板生成素临床耐受性试验[J].中华医学杂志,2001,81(24):1508-1511. 被引量:35
  • 8赵永强,李敬东.第九届全国血栓与止血学术会议纪要[J].中华内科杂志,2004,43(2):148-149. 被引量:4

共引文献34

同被引文献193

引证文献34

二级引证文献162

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部